Intranasal Dexamedotomidine Vs intranasal Midazolam in pediatric patients undergoing transcatheter ventricular septal defect (VSD) closure

A comparative study between intranasal dexamedotomidine and intranasal midazolam. Should preoperative sedation be a standard of care in pediatric patients undergoing transcatheter closure of VSD?

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202305793236698

Enrollment

Registered

2023-05-05

Start date

2023-04-08

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatrics Cardiology

Interventions

Intranasal dexmedetodine

intranasal midazolam

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children of either sex with age ranging from 3 to 12 years old Children with simple congenital heart disease (VSD) undergoing elective cardiac catheterization No coexisting cardiac/medical problems Normal Lab investigations results

Exclusion criteria

Exclusion criteria: Parent refusal Uncooperative patient Allergy to the study drug Any nasal disorder that may interfere with nasal administration of drugs as recurrent nasal bleeding or nasal masses, obstructive pharyngeal or laryngeal pathology Mental retardation.

Design outcomes

Primary

Measure	Time frame
good sedation , Ramsay scale, child parent separation score;faster induction of anesthesia	—

Secondary

Measure	Time frame
maintained hemodynamics;recovery state	—

Countries

Egypt

Contacts

Public ContactSally Hamdy

lecturer of anaesthesia

sallyhamdy44@gmail.com+201001098885

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026